Early results of valved bovine jugular vein conduit versus bicuspid homograft for right ventricular outflow tract reconstruction

Multicenter Experience Evaluating Transcatheter Pulmonary Valve Replacement in Bovine Jugular Vein (Contegra) Right Ventricle to Pulmonary Artery Conduits

“…[12][13][14]22 However, the data comparing homograft and Contegra performance are mixed with other studies showing comparable conduit longevity. [5][6][7][8][9][10] In this study, the primary indication for TPVR was stenosis or mixed stenosis and regurgitation. There was relatively even distribution of obstruction location along the length of the conduit, and there were no reported cases of distal conduit aneurysm or dissection before TPVR.…”

“…[3][4][5] Although one study found Contegra conduits to have superior durability to homograft conduits, the majority of studies have shown no significant differences in performance between the conduit types. [5][6][7][8][9][10][11] A small number of studies have reported higher risks of infective endocarditis (IE), distal conduit obstruction, and aneurysm formation as mechanisms of Contegra failure relative to homograft conduits. [12][13][14][15][16][17] The purpose of this retrospective multicenter study was to expand our understanding of outcomes after TPVR within the Contegra conduit, including responsiveness to angioplasty and stenting; procedural complications such as conduit disruption, hemodynamic results, intermediate-term valve performance, and endocarditis risk.…”

Valved Conduits Right Ventricle to Pulmonary Artery for Complex Congenital Heart Defects

“…The bovine jugular vein (Contegra®, Medtronic Inc., Minneapolis, MN), containing a trileaflet valve, was introduced into clinical practice as an alternative to the use of homografts in 1999 and has provided encouraging results in several reported clinical series, with follow-up reaching more than 10 years (37)(38)(39)(40)(41)(42)(43)(44)(45).…”

“…structural continuity between the wall of the jugular vein of the conduit and the valve leaflets, which provides optimal hemodynamics because of the ideal effective orifice area b. unlimited "off-the-shelf" availability in sizes from 12 to 22 mm diameter, representing a good alternative to the homograft shortage, particularly in the smaller sizes c. availability of a long length at both inflow and outflow that obviates the need for either proximal or distal augmentation; this facilitates conduit tailoring and positioning which helps to avoid potential distortion and sternal compression d. exceptional reports of antigenic reaction, due to glutaraldehyde fixation In contrast to the good clinical results obtained in several institutions (37)(38)(39)(40)(41)(42)(43)(44)(45), a disturbing sequence of publications reported stenosis at the level of the distal anastomosis of the conduit, with proximal conduit dilatation, aneurysm or pseudo-aneurysm, in between 6 and 50% of patients (39,40,42,(46)(47)(48)(49)(50)(51)(52)(53)(54).…”

O conduto valvulado bovino contegra, um biomaterial para o tratamento cirúrgico de cardiopatias congênitas

“…During the follow-up period, conduit valve was absent of regurgitation in 17.2-77.5% 6,9,13 , trivially regurgitant in 31-79.4% 9,13 , mildly regurgitant in 24-58.3% 9,15 , and moderately regurgitant in 3.4-8.6%…”